NCT02299141View on ClinicalTrials.gov

Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 7, 2015

Primary Completion Date

January 9, 2020

Study Completion Date

April 23, 2025

Conditions
Carcinoma, Non-Small-Cell LungNon-Small Cell Lung CancerNonsmall Cell Lung Cancer
Interventions
DRUG

Nintedanib

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

National Comprehensive Cancer Network

NETWORK

lead

Washington University School of Medicine

OTHER

NCT02299141 - Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter